Dyadic Q1 2026 revenue up 182% to $1.11M; net loss narrows to $(0.05)/share

DYADIC INTERNATIONAL INC

2026-Q1 EPS reported -$0.05 vs consensus -$0.04 ▼ miss (-22.5%)

Q1 revenue $1,110,956 vs $393,572 YoY; net loss $(0.05)/share vs $(0.07) prior year.
Cash and investments $6.6M as of March 31, 2026, down from $8.6M at Dec 31, 2025.
Received initial purchase orders for recombinant bovine transferrin from cultivated meat customers.
Proliant Health launched AlbuFree™ DX, with Dyadic entitled to profit share; expanded Fermbox Bio collaboration.
Signed OEM distribution agreement with IBT Bioservices; advanced Gates Foundation RSV/malaria and CEPI/FBS H5 programs.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.